- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.03. | CalciMedica: NASDAQ bemängelt Börsenwert und Aktienkurs - Delisting droht | 2 | Investing.com Deutsch | ||
| 18.03. | CalciMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.03. | CalciMedica, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| CALCIMEDICA Aktie jetzt für 0€ handeln | |||||
| 03.03. | CalciMedica GAAP EPS of -$1.97 | 1 | Seeking Alpha | ||
| 03.03. | CalciMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.03. | CalciMedica, Inc.: CalciMedica Reports 2025 Financial Results and Provides Clinical Updates | 662 | PR Newswire | Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related... ► Artikel lesen | |
| 30.01. | Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CalciMedica Halts KOURAGE | 839 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeutic... ► Artikel lesen | |
| 29.01. | This CalciMedica Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday | 16 | Benzinga.com | ||
| 28.01. | CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis | 10 | Benzinga.com | ||
| 28.01. | CalciMedica stock craters as calcium channel inhibitor trial stopped over 'safety concern' | 1 | FierceBiotech | ||
| 28.01. | CalciMedica-Aktie bricht nach Studienabbruch zu Nierenversagen um 80 % ein | 8 | Investing.com Deutsch | ||
| 28.01. | CalciMedica discontinues AKI trial following safety concerns | 1 | Investing.com | ||
| 28.01. | CalciMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.01. | CalciMedica, Inc.: CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation | 720 | PR Newswire | Safety concern warrants reevaluation of study design, including enrollment criteria
Potential future trial with Auxora in AKI to be evaluated after data analysis
... ► Artikel lesen | |
| 02.12.25 | Oppenheimer reiterates Outperform rating on CalciMedica stock ahead of key trial | 4 | Investing.com | ||
| 12.11.25 | CalciMedica, Inc.: CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates | 407 | PR Newswire | Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026
Positive discussions with... ► Artikel lesen | |
| 06.11.25 | CalciMedica, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.10.25 | CalciMedica partners with Telperian to use AI for clinical trial analysis | 1 | Investing.com | ||
| 14.10.25 | CalciMedica, Inc.: CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora | 233 | PR Newswire | AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations and efficacy endpoints for upcoming pivotal trials
LA JOLLA... ► Artikel lesen | |
| 12.08.25 | CalciMedica, Inc.: CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates | 239 | PR Newswire | Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) with respiratory failure; data expected in early 2026
Productive initial meeting... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 74,25 | -0,07 % | JETZT über 50 % KURSPOTENZIAL!? BioNTech, TUI und Bayer-Partner MustGrow | Lust auf ein Investment in einen Geheimtipp mit riesigem Marktpotenzial? Dann ist die Aktie von MustGrow interessant. Das Unternehmen wird mit unter 40 Mio. CAD bewertet. Die biologischen und regenerativen... ► Artikel lesen | |
| MODERNA | 41,725 | -0,78 % | Moderna vor entscheidender Bewährungsprobe | Moderna steht derzeit wieder stärker im Fokus technischer Beobachter. Im Chartbild zeigen sich Hinweise auf eine Stabilisierung Den vollständigen Artikel lesen ... ► Artikel lesen | |
| AMGEN | 303,90 | -0,23 % | Amgen: Repatha Cuts Risk Of First Major Cardiovascular Events By 31% In High-risk Patients Without Known Significant Atherosclerosis | Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention
VESALIUS-CV Subgroup Findings Reinforce Benefit... ► Artikel lesen | |
| NOVAVAX | 6,967 | -1,26 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| STRYKER | 284,10 | -0,18 % | Stryker, Zimmer Biomet & mehr Dividenden im global market - Ex-Tag 31.03.2026 | ||
| BIOGEN | 163,75 | +0,09 % | Biogen Sayd FDA Grants Approval For High-Dose SPINRAZA Regimen For SMATreatment | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Monday that the High Dose Regimen of SPINRAZA (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food... ► Artikel lesen | |
| ILLUMINA | 105,68 | +0,27 % | Argus hebt Illumina-Kursziel wegen neuer Produkte auf 145 US-Dollar an | ||
| VIKING THERAPEUTICS | 26,190 | +0,27 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| MAINZ BIOMED | 0,416 | -1,54 % | MAINZ BIOMED N.V. - 8-K, Current Report | ||
| INTELLIA THERAPEUTICS | 10,225 | +0,49 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 37,200 | +0,54 % | Tempus AI Enters Collaboration With Daiichi Sankyo | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Tempus AI announced a strategic collaboration with Daiichi Sankyo (4568.T) for accelerating the clinical development and differentiation of an antibody drug... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,238 | -0,27 % | BioCryst strebt Milliardenumsatz an und stärkt HAE-Portfolio mit Navenibart | ||
| BIOMARIN PHARMACEUTICAL | 47,870 | +0,13 % | BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations | ||
| SAREPTA THERAPEUTICS | 17,510 | -1,90 % | SRPT Stock Surges on Promising Early Results From siRNA Programs | ||
| EXELIXIS | 36,890 | +0,79 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen |
CALCIMEDICA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,530 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALCIMEDICA INC finden Sie auf Wallstreet Online.